The Series E round, which was led by existing investors General Catalyst and Kinnevik, included participation from Merck Global Health Innovation Fund, Microsoft Ventures and others.
Women continue to play an unfortunately small role in venture capital.
Niall O’Donnell fancies himself an archaeologist of the pharmaceutical persuasion. His firm, RiverVest Ventures, is scoping out the failed and forgotten drugs of big pharma, building companies to repurpose these benched meds for new indications. The aim is to find drugs that have passed for safety in clinical trials, but may have shown limited efficacy […]
Digital health is a popular business these days, but it’s also a tricky one. In theory, remote monitoring and engagement products have the potential to drive long-term cost savings, but robust data is lacking and consumer adoption so far has been relatively low. In a guest article for Re/code, Dr. Beth Seidenberg, former chief medical […]
As investments in life science companies have dipped over the past few years, some investors have scaled back investments or walked away from the sector all together. But based on a tally by investment research firm PitchBook in its 2013 Venture Capital Healthcare Report, several firms have made 10 or more investments in pharmaceutical, medical […]
Piggybacking off a $21 million round completed last year, Elcelyx Therapeutics has secured a $20 million series C to fund late-stage clinical development of its drug candidates for type 2 diabetes and weight loss. The round was led by GSM Fund LLC with participation from previous investors Morgenthaler Ventures, Kleiner Perkins Caufield & Byers and […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Kleiner Perkins Caufield & Byers, a venture firm that makes the life sciences one of its four main focuses, may have its eye on a new fund to invest in cloud computing. Bloomberg News is reporting that KPCB partner Matt Murphy and other partners “have talked about” investing $100 million this year in cloud computing […]
Venture capital investment in the life sciences has fallen 39 percent over the past three years as the costly, lengthy process of getting approval for pharmaceuticals from the Food and Drug Administration has spurred companies to shift their investments to overseas markets in Europe and Asia. According to the survey of 150 venture capital firms, […]
